Ondine announces Periowave presentation at IADR annual meeting

    VANCOUVER, July 2 /CNW/ - Ondine Biopharma Corporation (TSX: OBP; AIM:
OBP), a medical technology company developing photodisinfection-based
products, today announced that data from a study evaluating its Periowave
Photodynamic Disinfection System will be presented at the International
Association for Dental Research (IADR) 86th General Session & Exhibition in
Toronto, Ontario on Thursday, July 3, 2008.
    A poster presentation, entitled, "In vitro Bactericidal Efficacy of
Periowave Photodynamic Disinfection System", based on research conducted by
Loma Linda University School of Dentistry (Loma Linda, California), will be
presented on Thursday, July 3, 2008 from 3:30 pm to 4:45 pm (Metro Toronto
Convention Centre Exhibit Hall D-E, abstract 1281).
    "Periowave(TM) was used in this study to eradicate Gram-negative bacteria
including E. faecalis, which can be difficult to kill even using bleach
disinfection," stated Dr. Nicolas Loebel, Ondine's Chief Technology Officer.
"The bacteria are unaffected by the light or the photosensitizer when used
alone. When exposed to the Periowave(TM) Photodisinfection System, these
virulent pathogens are completely eliminated within 60 seconds. Because
Periowave(TM) works so differently to antibiotics, it does not increase
bacterial resistance - an important advantage as more and more bacteria
develop immunity to the conventional agents used today. Periowave(TM) provides
the practitioner with a non-antibiotic alternative that has been proven safe
and effective in clinical practice, eradicating bacteria associated with many
different disease processes."
    Further details on the abstract are available at:

    About Periowave(TM)

    Periowave(TM) is a photodisinfection system commercialized by Ondine that
utilizes low-intensity lasers and microbiological stains to target and destroy
microbial pathogens and reduce the symptoms of disease. The photodisinfection
technology was developed by Professor Michael Wilson and colleagues at the
Eastman Dental Institute, University College London, and licensed to Ondine by
UCL Business plc, University College London. Periowave(TM) is currently
approved in Canada and the European Union for several oral indications.
Additional information about Periowave(TM) is available at www.periowave.com

    About Ondine Biopharma Corporation

    Ondine is developing non-antibiotic therapies for the treatment of a
broad spectrum of bacterial, fungal and viral infections. The Company is
focused on developing and commercializing leading edge products utilizing its
patented light-activated technology. Photodisinfection provides broad-spectrum
antimicrobial efficacy without encouraging the formation and spread of
antibiotic resistance. The Company is based in Vancouver, British Columbia,
Canada, with a research laboratory in Bothell, Washington, and an
international office in St Michael, Barbados. For additional information,
please visit the Company's website at: www.ondinebiopharma.com

    Forward-Looking Statements:

    Certain statements contained in this release containing words like
"believe", "intend", "may", "expect" and other similar expressions, are
forward-looking statements that involve a number of risks and uncertainties.
Factors that could cause actual results to differ materially from those
projected in the Company's forward-looking statements include the following:
market acceptance of our technologies and products; our ability to obtain
financing; our financial and technical resources relative to those of our
competitors; our ability to keep up with rapid technological change;
government regulation of our technologies; our ability to enforce our
intellectual property rights and protect our proprietary technologies; the
ability to obtain and develop partnership opportunities; the timing of
commercial product launches; the ability to achieve key technical milestones
in key products and other risk factors identified from time to time in the
Company's filings.

    The TSX Exchange has not reviewed and does not accept responsibility for
    the adequacy or accuracy of this release.

For further information:

For further information: Carolyn Cross, President and Chief Executive
Officer, Ondine Biopharma Corporation, (604) 669-0555,
ccross@ondinebiopharma.com; Christina Bessant/Adam Peeler, Investor Relations,
The Equicom Group Inc., (416) 815-0700 ext. 269, cbessant@equicomgroup.com;
Canaccord Adams Ltd, Nominated Adviser & Broker, Neil Johnson/Ryan Gaffney,
+4420 7050 6500

Organization Profile


More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890